Department of Neurology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Rui Jin 2nd Road 197, Shanghai, 200025 China.
Department of Neurology, The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China.
Transl Neurodegener. 2014 Dec 5;3(1):26. doi: 10.1186/2047-9158-3-26. eCollection 2014.
Chronic levodopa (L-dopa) treatment in Parkinson's disease (PD) is often associated with the development of motor complications, but the corresponding epidemiological data is rare in Chinese PD patients. The present survey was to investigate the prevalence rate of wearing-off (WO) and dyskinesia among the patients with PD in China.
From May 2012 to October 2012, a 3-step registry survey for wearing off (WO) and dyskinesia patients with PD receiving levodopa therapy was performed simultaneously at 28 movement disorders clinics in China.
There were 1,558 PD patients fulfilling the inclusion criteria. Among them, 1,051 had at least one positive response of 9-item wearing off questionnaire (WOQ-9), 724 and 160 patients were finally diagnosed with WO and dyskinesia by movement disorders specialists, respectively. The overall prevalence rates of WO and dyskinesia were 46.5% (95% CI 44.0% - 48.9%) and 10.3% (95% CI 8.8% - 11.8%), respectively. The mean score of WOQ-9 for those with WO was 3.8 (SD = 1.8), with movement slowness being the most common motor symptoms and pain/aching being the most common non-motor symptoms. Better improvement of motor symptoms (n = 354, 87.8%) and long-term disease control and drug selection (n = 288, 71.5%) were the two most frequently considered factors when movement disorders specialists adjusted therapeutic strategies for patients with WO.
This survey provided the first multi-center epidemiological data of motor complications among PD patients on L-dopa therapy from mainland China. WO prevalence rate among Chinese PD patients was in line with, while dyskinesia prevalence rate was lower than previous reports from other Countries.
帕金森病(PD)患者长期接受左旋多巴(L-dopa)治疗常伴有运动并发症的发生,但中国 PD 患者的相关流行病学数据较为罕见。本研究旨在调查中国 PD 患者中发生剂末现象(WO)和运动障碍的患病率。
2012 年 5 月至 2012 年 10 月,中国 28 家运动障碍疾病诊疗中心同步开展了一项左旋多巴治疗的 PD 患者 WO 和运动障碍的 3 步登记研究。
共纳入 1558 例符合条件的 PD 患者。其中,1051 例患者对 9 项 WO 问卷(WOQ-9)至少有一个阳性反应,724 例和 160 例患者最终被运动障碍专家诊断为 WO 和运动障碍,WO 和运动障碍的总患病率分别为 46.5%(95%CI 44.0% - 48.9%)和 10.3%(95%CI 8.8% - 11.8%)。WO 患者的 WOQ-9 平均得分为 3.8(SD=1.8),运动迟缓是最常见的运动症状,疼痛/酸痛是最常见的非运动症状。改善运动症状(n=354,87.8%)和长期疾病控制及药物选择(n=288,71.5%)是运动障碍专家调整 WO 患者治疗策略时最常考虑的两个因素。
本研究提供了中国大陆左旋多巴治疗 PD 患者运动并发症的首个多中心流行病学数据。中国 PD 患者 WO 的患病率与其他国家的报告相似,而运动障碍的患病率则低于其他国家的报告。